Hospital
South Central Regional Medical Center
South Central Regional Medical Center was paid $48.01M by Medicaid between Jan 2018 and Dec 2024, across 336 billing codes. Its largest line is 99284, emergency room visit (serious) — 15% of everything it billed.
33Billing provider infoSOUTH CENTRAL REGIONAL MEDICAL CENTER
LAUREL, MS 39440
LAUREL, MS 39440
33aNPI1619973542assigned 06/24/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$48.01M
24GClaims1,363,043
24DCodes billed336
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Mississippi
Rank by total paid#7 of 77
Median peer was paid$8.23M
This provider vs. median5.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 197,665 | $6.44M | |
| 2019 | 221,658 | $7.37M | |
| 2020 | 175,147 | $5.94M | |
| 2021 | 162,119 | $6.74M | |
| 2022 | 218,116 | $7.44M | |
| 2023 | 212,307 | $8.11M | |
| 2024incomplete | 176,031 | $5.98M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 35,467 | 29,779 | $7.01M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 41,559 | 35,887 | $6.18M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.3% | 21,436 | 17,188 | $4.48M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.4% | 21,835 | 17,536 | $2.13M |
| G0378 | Hospital observation service, per hour | 4.1% | 11,237 | 5,420 | $1.96M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.9% | 24,440 | 5,625 | $1.39M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.7% | 60,568 | 12,208 | $1.32M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.1% | 10,667 | 7,602 | $1.01M |
| A0425 | Ground mileage, per statute mile | 2.1% | 20,826 | 12,092 | $996K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.1% | 5,969 | 5,220 | $990K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.8% | 27,761 | 6,246 | $867K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.6% | 11,283 | 4,426 | $787K |
324 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 8,574 | $760K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.5% | 4,503 | $741K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.5% | 18,011 | $698K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 19,540 | $641K |
| 71045 | Radiologic examination, chest; single view | 1.3% | 18,228 | $610K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.3% | 4,866 | $609K |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 13,668 | $583K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 5,393 | $550K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 25,395 | $544K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 9,001 | $520K |
| J0897 | Injection, denosumab, 1 mg | 1.1% | 963 | $517K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.0% | 10,051 | $499K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.0% | 1,954 | $484K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,681 | $464K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 34,829 | $418K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 12,025 | $378K |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 7,107 | $351K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 8,598 | $341K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 598 | $312K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 65,367 | $307K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,603 | $271K |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 61 | $265K |
| 97161 | <1% | 6,353 | $258K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 761 | $240K |
| A0429 | Emergency ambulance ride, basic life support | <1% | 6,892 | $221K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 5,924 | $208K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 38,083 | $190K |
| 86900 | <1% | 3,522 | $187K | |
| 80053 | Comprehensive metabolic panel | <1% | 25,167 | $163K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 12,181 | $153K |
| 96367 | <1% | 2,872 | $153K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,462 | $151K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 888 | $150K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 2,559 | $148K |
| 83880 | <1% | 8,061 | $146K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,049 | $135K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,728 | $133K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 3,419 | $131K |
| 92523 | <1% | 938 | $130K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 1,623 | $126K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,621 | $123K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,449 | $121K |
| 74022 | <1% | 1,889 | $121K | |
| 84484 | <1% | 18,763 | $116K | |
| 97113 | <1% | 3,694 | $115K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 766 | $115K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 5,215 | $106K |
| 95819 | <1% | 865 | $99K | |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 6,694 | $93K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,562 | $91K |
| 83735 | <1% | 24,814 | $88K | |
| 74018 | <1% | 2,007 | $81K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 7,915 | $80K |
| 36415 | Collection of venous blood by venipuncture | <1% | 36,088 | $79K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,076 | $78K |
| 73560 | <1% | 2,170 | $77K | |
| 97116 | <1% | 9,430 | $76K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 265 | $72K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,353 | $70K |
| 97165 | <1% | 1,983 | $68K | |
| 80306 | <1% | 6,138 | $67K | |
| 81003 | <1% | 41,247 | $62K | |
| 93971 | <1% | 1,452 | $61K | |
| 73610 | <1% | 1,372 | $61K | |
| 80076 | <1% | 12,664 | $61K | |
| 87088 | <1% | 11,056 | $60K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,432 | $60K |
| 86850 | <1% | 2,593 | $59K | |
| 86901 | <1% | 3,521 | $58K | |
| 97014 | <1% | 5,687 | $56K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,763 | $56K |
| 73630 | <1% | 1,348 | $56K | |
| 76000 | <1% | 782 | $55K | |
| 73130 | <1% | 1,225 | $55K | |
| 73030 | <1% | 1,658 | $55K | |
| 72170 | <1% | 1,268 | $54K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,498 | $52K |
| J3490 | Unclassified drugs | <1% | 10,152 | $51K |
| 83690 | <1% | 11,781 | $51K | |
| 87420 | <1% | 4,550 | $49K | |
| 72110 | <1% | 884 | $47K | |
| 84703 | <1% | 8,151 | $47K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,215 | $46K |
| 83874 | <1% | 7,996 | $46K | |
| 87186 | <1% | 7,137 | $44K | |
| 82553 | <1% | 8,505 | $44K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 111 | $43K |
| 96523 | <1% | 1,964 | $43K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 407 | $41K |
| 70486 | <1% | 686 | $41K | |
| 82550 | <1% | 10,958 | $39K | |
| 84702 | <1% | 3,399 | $39K | |
| 96415 | <1% | 631 | $39K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,547 | $36K |
| 99201 | <1% | 2,614 | $36K | |
| 76801 | <1% | 468 | $35K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 87 | $35K |
| 81025 | <1% | 5,558 | $34K | |
| 0598T | <1% | 1,932 | $33K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 474 | $33K |
| 87040 | <1% | 5,514 | $31K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,552 | $31K |
| 17110 | <1% | 300 | $30K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 976 | $29K |
| 96417 | <1% | 669 | $28K | |
| 97597 | <1% | 541 | $28K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,601 | $27K |
| 36430 | <1% | 289 | $27K | |
| 82803 | <1% | 2,064 | $25K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 430 | $25K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 405 | $24K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 103 | $24K |
| 11102 | <1% | 278 | $24K | |
| 85610 | <1% | 10,535 | $23K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,794 | $23K |
| 87070 | <1% | 3,722 | $23K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 20,379 | $23K |
| 76536 | <1% | 382 | $22K | |
| 73110 | <1% | 471 | $21K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,394 | $21K |
| 87807 | <1% | 1,786 | $20K | |
| 78431 | <1% | 28 | $18K | |
| 83605 | <1% | 3,353 | $18K | |
| 87077 | <1% | 3,276 | $17K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,787 | $17K |
| 29581 | <1% | 522 | $16K | |
| 85379 | <1% | 2,831 | $14K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 209 | $14K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 185 | $14K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 7,482 | $14K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 195 | $14K |
| 82728 | <1% | 2,447 | $14K | |
| 82077 | <1% | 1,322 | $14K | |
| 86920 | <1% | 200 | $13K | |
| 51702 | <1% | 391 | $13K | |
| 93970 | <1% | 181 | $13K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 616 | $13K |
| 76770 | <1% | 222 | $12K | |
| 84466 | <1% | 2,207 | $12K | |
| 83615 | <1% | 3,580 | $12K | |
| 49452 | <1% | 41 | $11K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 445 | $11K |
| 71250 | <1% | 275 | $11K | |
| 80061 | Lipid panel | <1% | 1,227 | $11K |
| 85730 | <1% | 3,205 | $11K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 410 | $10K |
| J2704 | Injection, propofol, 10 mg | <1% | 4,839 | $10K |
| 82010 | <1% | 2,477 | $10K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 22,331 | $10K |
| 73590 | <1% | 206 | $9K | |
| 95811 | <1% | 25 | $9K | |
| 84439 | <1% | 1,495 | $9K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13,894 | $8K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,981 | $8K |
| 84238 | <1% | 698 | $8K | |
| 87205 | <1% | 2,796 | $8K | |
| 73090 | <1% | 165 | $8K | |
| 82962 | <1% | 3,882 | $7K | |
| J1815 | Injection, insulin, per 5 units | <1% | 4,500 | $7K |
| 12001 | <1% | 68 | $7K | |
| 86738 | <1% | 619 | $7K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 2,008 | $6K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 3,316 | $6K |
| 83540 | <1% | 2,253 | $6K | |
| 82565 | <1% | 1,928 | $6K | |
| 76642 | <1% | 154 | $6K | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 78 | $6K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 61 | $6K |
| 73080 | <1% | 119 | $5K | |
| 97162 | <1% | 147 | $5K | |
| 80143 | <1% | 496 | $5K | |
| 80179 | <1% | 452 | $5K | |
| 29125 | <1% | 79 | $4K | |
| 72050 | <1% | 82 | $4K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 53 | $4K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,245 | $4K |
| 82607 | <1% | 605 | $4K | |
| 73562 | <1% | 100 | $4K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 4,299 | $4K |
| 88720 | <1% | 543 | $4K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,397 | $4K |
| 87507 | <1% | 18 | $3K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 34 | $3K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 742 | $3K |
| 86140 | <1% | 967 | $3K | |
| 82784 | <1% | 489 | $3K | |
| 94200 | <1% | 185 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 551 | $3K |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 11,298 | $3K |
| 87046 | <1% | 226 | $3K | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 452 | $3K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 74 | $3K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 5,157 | $3K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 92 | $3K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 9,368 | $3K |
| 85651 | <1% | 1,014 | $3K | |
| 12011 | <1% | 34 | $3K | |
| 94762 | <1% | 51 | $3K | |
| 43760 | <1% | 39 | $3K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 5,948 | $3K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 28 | $2K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 153 | $2K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 9,140 | $2K |
| 71101 | <1% | 36 | $2K | |
| 87899 | <1% | 175 | $2K | |
| 73502 | <1% | 73 | $2K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 13,669 | $2K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,631 | $2K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 88 | $2K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,414 | $2K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 28 | $2K |
| 93922 | <1% | 41 | $2K | |
| 82947 | <1% | 426 | $2K | |
| 90715 | <1% | 1,883 | $1K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,431 | $1K |
| 93880 | <1% | 25 | $1K | |
| 87210 | <1% | 323 | $1K | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 60 | $1K |
| J7510 | Prednisolone oral, per 5 mg | <1% | 2,143 | $1K |
| 92610 | <1% | 61 | $1K | |
| 73552 | <1% | 29 | $1K | |
| 76870 | <1% | 16 | $1K | |
| 83921 | <1% | 139 | $1K | |
| 72131 | <1% | 28 | $1K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 15 | $1K |
| 87045 | <1% | 123 | $993.39 | |
| 82746 | <1% | 182 | $973.14 | |
| 82150 | <1% | 216 | $931.03 | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 455 | $915.20 |
| 74019 | <1% | 12 | $909.66 | |
| 84550 | <1% | 302 | $867.29 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,860 | $846.02 |
| 85045 | <1% | 436 | $812.10 | |
| 77065 | Tomosynthesis, mammo | <1% | 25 | $808.79 |
| 87015 | <1% | 250 | $805.02 | |
| 17000 | <1% | 42 | $782.46 | |
| 84165 | <1% | 167 | $712.66 | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 16 | $641.52 |
| 82140 | <1% | 148 | $624.90 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,114 | $597.68 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 3,831 | $593.44 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,978 | $589.33 |
| 90686 | <1% | 54 | $532.84 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 1,319 | $522.25 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 448 | $518.17 |
| 82800 | <1% | 149 | $457.25 | |
| 99152 | <1% | 1,348 | $440.00 | |
| 96376 | <1% | 1,895 | $435.50 | |
| 36600 | <1% | 17 | $345.76 | |
| 85018 | <1% | 255 | $324.19 | |
| 82570 | <1% | 79 | $290.48 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,796 | $207.16 |
| 94760 | <1% | 8,799 | $205.16 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 615 | $199.00 |
| Q0092 | Set-up portable x-ray equipment | <1% | 868 | $194.17 |
| 87209 | <1% | 13 | $194.16 | |
| 80185 | <1% | 14 | $191.36 | |
| 83883 | <1% | 35 | $178.90 | |
| 82378 | <1% | 35 | $170.60 | |
| 84155 | <1% | 188 | $170.35 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,405 | $143.90 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 276 | $141.00 |
| 84156 | <1% | 49 | $135.30 | |
| 87177 | <1% | 13 | $96.12 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 672 | $81.60 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 1,432 | $74.04 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 738 | $72.93 |
| 11045 | <1% | 601 | $70.89 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 311 | $65.16 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,891 | $54.82 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 235 | $27.50 |
| 80069 | <1% | 58 | $25.17 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,062 | $19.60 |
| G0008 | Administration of influenza virus vaccine | <1% | 18 | $15.88 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 70 | $9.81 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 54 | $7.70 |
| 83521 | <1% | 15 | $6.90 | |
| 00840 | <1% | 155 | $6.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 52 | $0.11 |
| G8990 | Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 113 | $0.00 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 1,067 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 635 | $0.00 |
| J7699 | Noc drugs, inhalation solution administered through dme | 0% | 29 | $0.00 |
| J2252 | Injection, midazolam in 0.8% sodium chloride, intravenous, not therapeutically equivalent to j2250, 1 mg | 0% | 71 | $0.00 |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | 0% | 595 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 130 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 256 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 19 | $0.00 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | 0% | 56 | $0.00 |
| J7070 | Infusion, d5w, 1000 cc | 0% | 109 | $0.00 |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 0% | 108 | $0.00 |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | 0% | 13 | $0.00 |
| 84145 | 0% | 53 | $0.00 | |
| 00731 | 0% | 13 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 19 | $0.00 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 13 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 15 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 753 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 600 | $0.00 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 1,590 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 2,982 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 973 | $0.00 |
| A4215 | Needle, sterile, any size, each | 0% | 14 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 577 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 112 | $0.00 |
| 0599T | 0% | 551 | $0.00 | |
| 80320 | 0% | 349 | $0.00 | |
| C1769 | Guide wire | 0% | 1,051 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 63 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 901 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 178 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 51 | $0.00 |
| J3410 | Injection, hydroxyzine hcl, up to 25 mg | 0% | 39 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 124 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 59 | $0.00 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 49 | $0.00 |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 191 | $0.00 |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 0% | 28 | $0.00 |
| 96368 | 0% | 35 | $0.00 | |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 47 | $0.00 |
| 80329 | 0% | 14 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 37 | $0.00 |
| G8992 | Other physical or occupational therapy primary functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 12 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 75 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialEAST, STEPHEN (CFO)
| Provider | Location | Paid |
|---|---|---|
| South Central Regional Medical Center | Laurel, MS | $178K |
| South Central Regional Medical Center | Laurel, MS | $14K |
| South Central Regional Medical Center | Laurel, MS | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.